NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

ImmuCell Corporation (ICCC) Stock Analysis

ImmuCell Corporation (ICCC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ICCC

$9.90

−$0.10 (−1.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICCC with… →

ICCC Key Statistics

As of Sep 4, 2026
Trading
Open
$9.97
Previous Close
$10.00
Day's Range
9.80–9.97
52-Week Range
4.52–12.10
Volume
11.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.55
Valuation
Market Cap
$89.91M
P/E Ratio
141.43
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.93
EPS (ttm)Profit attributable to each share over the last twelve months.
0.07
Financials (FY)
Revenue (FY)
$27.64M+4.34%
Net Income (FY)
−$1.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
2.57%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.08M
1-Year Return
+51.84%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
29.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ICCC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+60.98%
2025+19.42%
2024+1.18%
2023−16.56%
2022−23.75%
2021+34.45%
2020+15.53%
2019−26.95%
2018−19.80%
2017+47.73%
2016 (partial year)−24.01%

As of September 4, 2026.

ICCC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$27.64M−$1.04M−3.8%
2024$26.49M−$2.16M−8.1%
2023$17.47M−$5.77M−33.1%
2022$18.57M−$2.49M−13.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$27.64M$11.45M$1.65M−$1.04M−3.8%
2024$26.49M$7.94M−$1.64M−$2.16M−8.1%
2023$17.47M$3.87M−$5.75M−$5.77M−33.1%
2022$18.57M$7.65M−$2.30M−$2.49M−13.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICCC Valuation vs Biotechnology Median

Median of 656 stocks
MetricICCCBiotechnology medianvs median
P/E141.4312.5711.3x the median
P/S ratio2.9315.260.2x the median
Profit margin2.57%0.00%2.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ImmuCell Corporation (ICCC) carries a market capitalisation of $89.91M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

Over the past 52 weeks the price has ranged from $4.52 to $12.10. The most recent close on file for ICCC is $9.90, dated September 4, 2026. That is −$0.10 (−1.00%) against the previous close. The latest close sits 119.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $27.64M. That is +4.34% against the prior fiscal year, when revenue was $26.49M. The same year closed with a net loss of $1.04M. Profit margin runs at 2.57%. That is 2.6 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.07.

Across the 4 fiscal years on file, revenue moves from $18.57M in 2022 to $27.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 141.43 times earnings. That is 11.3 times the Biotechnology median of 12.57. The price-to-sales ratio is 2.93. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +51.84%. Across 10 years the annualized return works out at +3.15%. Beta against the wider market is reported at 0.55. Daily returns over the trailing 10 years annualize to a volatility of 52.7%.

Growth & Income

No dividend is on file for ICCC.

2026 is still running; the price is +60.98% year to date. The strongest complete calendar year on file is 2017 at +47.73%; the weakest is 2019 at −26.95%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

ImmuCell Corporation (ICCC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ImmuCell Corporation ICCC $89.91M 141.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. ImmuCell Corporation trades at a P/E of 141.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Visit website →